Systematic Reviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2021; 9(23): 6747-6758
Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6747
Safety of pancreatic surgery with special reference to antithrombotic therapy: A systematic review of the literature
Takahisa Fujikawa, Shigetoshi Naito
Takahisa Fujikawa, Shigetoshi Naito, Department of Surgery, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan
Author contributions: Fujikawa T designed and performed research, and analyzed data; Naito S also performed research; Fujikawa T prepared a manuscript and reviewed it.
Conflict-of-interest statement: The authors declare no relevant conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takahisa Fujikawa, FACS, MD, PhD, Chief Doctor, Department of Surgery, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu 802-8555, Japan. fujikawa-t@kokurakinen.or.jp
Received: January 29, 2021
Peer-review started: January 29, 2021
First decision: April 5, 2021
Revised: April 27, 2021
Accepted: July 6, 2021
Article in press: July 6, 2021
Published online: August 16, 2021
Processing time: 188 Days and 10.3 Hours
Core Tip

Core Tip: A total of 19 published articles on antithrombotic therapy and pancreatic surgery have been reviewed systematically. The articles showed that the risk of perioperative thromboembolic and/or bleeding complications in patients with heparin bridging or continued antiplatelets was not significantly higher than in patients with no antithrombotic or interrupted antiplatelets, although medical thromboprophylaxis for venous thromboembolism remains controversial when performing pancreatectomy for malignancy.